Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 268796, 6 pages
http://dx.doi.org/10.1155/2015/268796
Clinical Study

Ganglion Cell Complex Evaluation in Exudative Age-Related Macular Degeneration after Repeated Intravitreal Injections of Ranibizumab

1Ophthalmology Unit, NESMOS Department, Sant’Andrea Hospital, Faculty of Medicine and Psychology, “Sapienza” University of Rome, Via di Grottarossa 1035-1039, 00189 Rome, Italy
2Ophthalmology Unit, Azienda Policlinico Umberto I, “Sapienza” University of Rome, Viale del Policlinico 155, 00186 Rome, Italy

Received 21 August 2014; Revised 17 October 2014; Accepted 26 October 2014

Academic Editor: Antonio Ferreras

Copyright © 2015 Andrea Perdicchi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. C. W. Klaver, J. J. M. Assink, R. Van Leeuwen et al., “Incidence and progression rates of age-related maculopathy: the rotterdam study,” Investigative Ophthalmology and Visual Science, vol. 42, no. 10, pp. 2237–2241, 2001. View at Google Scholar · View at Scopus
  2. H. Oh, H. Takagi, C. Takagi et al., “The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes,” Investigative Ophthalmology and Visual Science, vol. 40, no. 9, pp. 1891–1898, 1999. View at Google Scholar · View at Scopus
  3. R. Steinbrook, “The price of sight—ranibizumab, bevacizumab, and the treatment of macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1409–1412, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. V. Fenicia, S. Abdolrahimzadeh, G. Mannino, S. Verrilli, M. Balestrieri, and S. M. Recupero, “Intravitrealbevacizumab in the successful management of choroidal metastases secondary to lung and breast cancer unresponsive to systemictherapy: a case series,” Eye, 2014. View at Publisher · View at Google Scholar
  5. V. Fenicia, M. Balestrieri, A. Perdicchi, G. Maraone, and S. M. Recupero, “Intravitreal injection of dexamethasone implant in serous macular detachment associated with Waldenström's disease,” Case Reports in Ophthalmology, vol. 4, no. 2, pp. 64–69, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Ciarnella, S. Verrilli, V. Fenicia et al., “Intravitreal ranibizumab and laser photocoagulation in the management of idiopathic juxtafoveolar retinal telangiectasia type 1: a case report,” Case Reports in Ophthalmology, vol. 3, no. 3, pp. 298–303, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. P. J. Rosenfeld, D. M. Brown, J. S. Heier et al., “Ranibizumab for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 355, no. 14, pp. 1419–1431, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Lambiase, S. Abdolrahimzadeh, and S. M. Recupero, “An update on intravitreal implants in use for eye disorders,” Drugs of Today, vol. 50, no. 3, pp. 239–249, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. R. L. Avery, D. J. Pieramici, M. D. Rabena, A. A. Castellarin, M. A. Nasir, and M. J. Giust, “Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration,” Ophthalmology, vol. 113, no. 3, pp. 363–372, 2006. View at Google Scholar
  10. D. Vavvas and D. J. D'Amico, “Pegaptanib (Macugen): treating neovascular age-related macular degeneration and current role in clinical practice,” Ophthalmology Clinics of North America, vol. 19, no. 3, pp. 353–360, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. P. Mitchell, J.-F. Korobelnik, P. Lanzetta et al., “Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials,” British Journal of Ophthalmology, vol. 94, no. 1, pp. 2–13, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Storkebaum, D. Lambrechts, and P. Carmeliet, “VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection,” BioEssays, vol. 26, no. 9, pp. 943–954, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. G. L. Scuderi, N. C. Cascone, F. Regine, A. Perdicchi, A. Cerulli, and S. M. Recupero, “Validity and limits of the rebound tonometer (ICare): clinical study,” European Journal of Ophthalmology, vol. 21, no. 3, pp. 251–257, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Lumbroso and R. Brancato, Guida pratica all’interpretazione dell'OCT, Editore I.N.C., Roma, Italy, 2004.
  15. http://www.oct-optovue.com/GCC-RTVue-version4.pdf.
  16. K. Yang and C. L. Cepko, “Flk-1, a receptor for vascular endothelial growth factor (VEGF), is expressed by retinal progenitor cells,” The Journal of Neuroscience, vol. 16, no. 19, pp. 6089–6099, 1996. View at Google Scholar · View at Scopus
  17. I. Kim, A. M. Ryan, R. Rohan et al., “Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes,” Investigative Ophthalmology and Visual Science, vol. 40, no. 9, pp. 2115–2121, 1999. View at Google Scholar · View at Scopus
  18. R. E. Gilbert, D. Vranes, J. L. Berka et al., “Vascular endothelial growth factor and its receptors in control and diabetic rat eyes,” Laboratory Investigation, vol. 78, no. 8, pp. 1017–1027, 1998. View at Google Scholar · View at Scopus
  19. K. Nishijima, Y.-S. Ng, L. Zhong et al., “Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury,” The American Journal of Pathology, vol. 171, no. 1, pp. 53–67, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. J. M. Martinez-de-la-Casa, A. Ruiz-Calvo, F. Saenz-Frances et al., “Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab,” Investigative Ophthalmology and Visual Science, vol. 53, no. 10, pp. 6214–6218, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Nishimura, S. Machida, T. Harada, and D. Kurosaka, “Retinal ganglion cell function after repeated intravitreal injections of ranibizumab in patients with age-related macular degeneration,” Clinical Ophthalmology, vol. 6, no. 1, pp. 1073–1082, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. L. Wu, M. A. Martínez-Castellanos, H. Quiroz-Mercado et al., “Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the pan-american collaborative retina study group (PACORES),” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 246, no. 1, pp. 81–87, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. J. E. Kim, A. V. Mantravadi, E. Y. Hur, and D. J. Covert, “Short-term intraocular pressure changes immediately after intravitreal injections of antivascular endothelial growth factor agents,” The American Journal of Ophthalmology, vol. 146, no. 6, pp. 930.e1–934.e1, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. R. E. P. Frenkel, L. Mani, A. R. Toler, and M. P. C. Frenkel, “Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma,” American Journal of Ophthalmology, vol. 143, no. 6, pp. 1034–1035, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Flammer, “The concept of visual field defects,” Graefe's Archive for Clinical and Experimental Ophthalmology, vol. 224, pp. 389–392, 1986. View at Google Scholar
  26. L. Maffei and A. Fiorentini, “Electroretinographic responses to alternating gratings before and after section of the optic nerve,” Science, vol. 211, no. 4485, pp. 953–955, 1981. View at Publisher · View at Google Scholar · View at Scopus
  27. K. S. Kim, H. R. Chang, and S. Song, “Ischaemic change after intravitreal bevacizumab (Avastin) injection for macular oedema secondary to non-ischaemic central retinal vein occlusion,” Acta Ophthalmologica, vol. 86, no. 8, pp. 925–927, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Yokoyama, T. Choshi, K. Kimoto, K. Shinoda, and K. Nakatsuka, “Retinal circulatory disturbances following intracameral injection of bevacizumab for neovascular glaucoma,” Acta Ophthalmologica, vol. 86, no. 8, pp. 927–928, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. R. Siliprandi, R. Canella, G. Carmignoto et al., “N-methyl-D-aspartate-induced neurotoxicity in the adult rat retina,” Visual Neuroscience, vol. 8, no. 6, pp. 567–573, 1992. View at Publisher · View at Google Scholar · View at Scopus
  30. V. E. S. Jeganathan and N. Verma, “Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration,” Current Opinion in Ophthalmology, vol. 20, no. 3, pp. 223–225, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. D. F. Martin, M. G. Maguire, G.-S. Ying, J. E. Grunwald, S. L. Fine, and G. J. Jaffe, “Ranibizumab and bevacizumab for neovascular age-related macular degeneration,” The New England Journal of Medicine, vol. 364, no. 20, pp. 1897–1908, 2011. View at Publisher · View at Google Scholar · View at Scopus